PMC:7600245 / 14105-14728 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T68","span":{"begin":366,"end":369},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma67095"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T48","span":{"begin":514,"end":522},"obj":"Disease"},{"id":"T49","span":{"begin":526,"end":538},"obj":"Disease"}],"attributes":[{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0020502"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T117","span":{"begin":68,"end":74},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T118","span":{"begin":143,"end":144},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T119","span":{"begin":214,"end":220},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T120","span":{"begin":289,"end":295},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T121","span":{"begin":475,"end":481},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T122","span":{"begin":485,"end":486},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T123","span":{"begin":604,"end":607},"obj":"http://purl.obolibrary.org/obo/CLO_0054061"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T131","span":{"begin":18,"end":27},"obj":"Chemical"},{"id":"T132","span":{"begin":28,"end":38},"obj":"Chemical"},{"id":"T133","span":{"begin":80,"end":89},"obj":"Chemical"},{"id":"T134","span":{"begin":125,"end":135},"obj":"Chemical"},{"id":"T135","span":{"begin":145,"end":152},"obj":"Chemical"},{"id":"T136","span":{"begin":229,"end":252},"obj":"Chemical"},{"id":"T137","span":{"begin":229,"end":239},"obj":"Chemical"},{"id":"T138","span":{"begin":240,"end":252},"obj":"Chemical"},{"id":"T139","span":{"begin":258,"end":270},"obj":"Chemical"},{"id":"T140","span":{"begin":422,"end":426},"obj":"Chemical"}],"attributes":[{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_16335"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_50266"},{"id":"A136","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_17326"},{"id":"A137","pred":"chebi_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/CHEBI_33838"},{"id":"A138","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_18036"},{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_18036"},{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":533,"end":538},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T103","span":{"begin":0,"end":113},"obj":"Sentence"},{"id":"T104","span":{"begin":114,"end":253},"obj":"Sentence"},{"id":"T105","span":{"begin":254,"end":417},"obj":"Sentence"},{"id":"T106","span":{"begin":418,"end":579},"obj":"Sentence"},{"id":"T107","span":{"begin":580,"end":623},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"344","span":{"begin":93,"end":97},"obj":"Gene"},{"id":"345","span":{"begin":0,"end":11},"obj":"Chemical"},{"id":"346","span":{"begin":18,"end":27},"obj":"Chemical"},{"id":"347","span":{"begin":125,"end":135},"obj":"Chemical"},{"id":"348","span":{"begin":229,"end":252},"obj":"Chemical"},{"id":"349","span":{"begin":258,"end":270},"obj":"Chemical"},{"id":"350","span":{"begin":514,"end":522},"obj":"Disease"},{"id":"351","span":{"begin":533,"end":538},"obj":"Disease"}],"attributes":[{"id":"A344","pred":"tao:has_database_id","subj":"344","obj":"Gene:43740578"},{"id":"A345","pred":"tao:has_database_id","subj":"345","obj":"MESH:C517546"},{"id":"A346","pred":"tao:has_database_id","subj":"346","obj":"MESH:D000241"},{"id":"A347","pred":"tao:has_database_id","subj":"347","obj":"MESH:C000606551"},{"id":"A349","pred":"tao:has_database_id","subj":"349","obj":"MESH:C005692"},{"id":"A350","pred":"tao:has_database_id","subj":"350","obj":"MESH:C000657245"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Galidesivir is an adenosine nucleoside analog (Figure 3) that is an active site inhibitor of RdRp (EC50 \u003c 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID (NCT03891420; n = 132) [44,45,46,47]."}